Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Black Box" For Protopic, Elidel Is "Blunt" But Necessary Instrument, Advisory Cmte. Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Although noting that data suggesting a cancer risk from the topical eczema treatments is not definitive, the panel concludes that a black box warning is the best approach to discourage off-label use. A medication guide should also be mandated, the committee says.
Advertisement

Related Content

Advisory Committee To Revisit Boxed Warning For Protopic, Elidel
Novartis, Astellas Intend To Disprove Eczema Treatments’ Cancer Risk
FDA Approves Boxed Warning On Cancer Risk For Elidel And Protopic
FDA Advisory Committees Are Platform For Politicized Discussion, Former Counsel Troy Says
Massachusetts Medicaid Adds Prior Authorization For Elidel, Protopic
Sucampo Halts Tacrolimus Eye Drop Program, Sues Fujisawa
Elidel Sales To Rebound In Early 2006 Despite Cancer Risk Concerns – Novartis
Novartis' Elidel, Fujisawa's Protopic To Add "Black Box" On Cancer Risk
Novartis Re-starts Elidel TV Ad Featuring Cartoon Superhero
Novartis Re-starts Elidel TV Ad Featuring Cartoon Superhero

Topics

Advertisement
UsernamePublicRestriction

Register

PS061560

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel